WAYRILZ

This brand name is authorized in United States. It is also authorized in Austria, Italy, Lithuania, Romania.

Active ingredients

The drug WAYRILZ contains one active pharmaceutical ingredient (API):

1	Rilzabrutinib UNII NWN58M4F5T - RILZABRUTINIB
	Rilzabrutinib is a selective, covalent, reversible inhibitor of Bruton's tyrosine kinase (BTK), with a tailored residence time at BTK to reduce off-target effects. In immune thrombocytopenia (ITP), rilzabrutinib mediates its therapeutic effect through multi-immune modulation by inhibiting B cell activation, interruption of FcγR mediated phagocytosis, and potentially amelioration of chronic inflammation associated with ITP.
	Read more about Rilzabrutinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
WAYRILZ Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
WAYRILZ Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
IT	Agenzia del Farmaco	052759014, 052759026, 052759038
LT	Valstybinė vaistų kontrolės tarnyba	1105616, 1105617, 1105618
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W71728001
US	FDA, National Drug Code	58468-0251